CD44, the transmembrane protein that is the receptor for matrix components such as hyaluronic acid selectin, collagen, and osteopontin, has been proven to help treat acute myeloid leukemia (AML) by inhibiting tumor proliferation, and increasing apoptosis (152, 153). This evidence concerns the gene CD44 and acute myeloid leukemia.